At mid-afternoon, we’ve seen some changes among today’s big movers. On the plus side are Medivation Inc. (NASDAQ: MDVN, Live Deal Inc. (NASDAQ: LIVE, RadiSys Corp. (NASDAQ: RSYS), Savient Pharmaceuticals Inc. (NASDAQ: SVNT), and Vringo Inc. (NASDAQ: VRNG).
Medivation has jumped nearly 25% to $69.12 after posting a new 52-week high of $70.87 earlier today. The development stage drug maker has reported highly positive results on a test of its late-stage prostate cancer treatment. We have more coverage here.
Live Deal is up nearly 25% at $5.47. The customer acquisition company got a capital infusion on Monday from the private equity division of Isaac Organization.
RadiSys is up nearly 22% at $7.35 in a 52-week range of $4.01-$9.38. The company has announced a ruggedized version of a Core processor from Intel Corp. (NASDAQ: INTC).
Savient is down more than 12% at $2.22. The drug company lost its CEO, who has joined Dendreon Corp. (NASDAQ: DNDN) as its new CEO.
Vringo is down nearly -6% at $1.32. The social media company is giving back some of the 30% gain it enjoyed yesterday.
The DJIA is up 1% at around 12,760, the S&P 500 is up 1.19% at about 1,328, and the Nasdaq Composite is up 1.33% at about 2,851.
Paul Ausick
Take Charge of Your Retirement In Just A Few Minutes (Sponsor)
Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance—and SmartAsset’s made it easier than ever for you to connect with a vetted financial advisor.
Here’s how it works:
- Answer a Few Simple Questions. Tell us a bit about your goals and preferences—it only takes a few minutes!
- Get Matched with Vetted Advisors Our smart tool matches you with up to three pre-screened, vetted advisors who serve your area and are held to a fiduciary standard to act in your best interests. Click here to begin
- Choose Your Fit Review their profiles, schedule an introductory call (or meet in person), and select the advisor who feel is right for you.
Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.